Purchase Option

$ 4400
$ 4000
$ 6000

Venous Thromboembolism Disease Pipeline Drugs Assessment: Clinical Trails Analysis, Player Profiles, Collaborations, Key Targets, Geographic Focus, and Data Publications, 2018

 

Venous Thromboembolism Disease Pipeline Drugs Assessment

 

Overview:

Venous Thromboembolismis a disease caused by clotting of blood in blood vessel which leads to restriction of blood flow within the circulatory system. Venous thromboembolism is classified into pulmonary embolism and deep vein thrombosis. Deep vein thrombosis is mainly occurred due to the clotting of the blood in the deep vein (commonly in the leg). The formed DVT clot breaks off and flows to the lungs known as pulmonary embolism which is a severe complication of deep vein thrombosis (DVT). Venous thromboembolism commonly occurs in aged persons with more than 60 years.

The symptoms associated with the venous thromboembolism include dilated blood veins in legs and chest, edema, fever, tachycardia, and dyspnea. Lower extremities are the most common site for DVT, but other locations affected include the mesenteric, upper extremities, pelvic veins, and cerebral vein. Venous Thromboembolism is treated by blood thinners, clot-busting drugs and surgery.

 

Segmentation:

By Trial Phase, Venous Thromboembolism pipeline drugs are segmented as:

  • Preclinical Trials
  • Phase 1
  • Phase 2
  • Phase 3
  • Phase 4

By Company, Venous Thromboembolism pipeline drugs are segmented as:

  • Pfizer
  • Bristol-Myers Squibb
  • Bayer
  • Janssen Research & Development, LLC
  • Daiichi Sankyo, Inc
  • BoehringerIngelheim
  • GlaxoSmithKline
  • Others

By Drugs, Venous Thromboembolism pipeline drugs are segmented as:

  • Rivaroxaban
  • Apixaban
  • Edoxaban
  • Tinzaparin
  • Betrixaban
  • Enoxaparin
  • Others

By Type of Condition, Venous Thromboembolism pipeline drugs are segmented as:

  • Deep vein thrombosis
  • pulmonary embolism

By Route of Administration, Venous Thromboembolismpipeline drugs are segmented as:

  • Oral
  • Parenteral

 

Space Analysis:

  • In March 2017, Daiichi Sankyo, Inc. commenced a phase 3, open-label, randomized, multi-center, controlled trial to evaluate the pharmacokinetics and pharmacodynamics of edoxaban and to compare the efficacy and safety of edoxaban with standard of care anticoagulant therapy in pediatric subjects from birth to less than 18 years of age with confirmed venous thromboembolism
  • In November 2015, Pfizer in collaboration with Bristol-Myers Squibb commenced a phase 4 randomized, open label, active controlled, safety and descriptive efficacy study in pediatric subjects requiring anticoagulation of apixaban for the treatment of venous thromboembolism
 

Report Description:

Venous Thromboembolism Disease Pipeline Drugs Assessment report studies the various therapeutics under clinical development for Venous Thromboembolism treatment along with targets for various drug candidate. The report provides plethora of information pertaining to trail phases, companies involved in the Venous Thromboembolism disease pipeline drugs development. This report studies the dynamics of the Venous Thromboembolism Disease Pipeline Drugs i.e. drivers, challenges and opportunities which are significantly impacting the product development. The report provides various information pertaining the clinical trials such as designation, grants, patents, and technology among others. Moreover, the report on Venous Thromboembolism disease pipeline drugs assessment comprehensively presents the geographic location, trial status information along with key players involved in the therapeutics development.

 

Key Features of the Report:

  • Provides the information related to universities and research institutes working in the therapeutics development
  • Report comprehensively covers the all active and discontinued studies
  • Studies the entire pipeline with special emphasis on companies actively involved in the therapeutics development
  • Presents the prominent targets for drug development in each stage of clinical trial
  • Provides the in-depth analysis on the each drug candidates in the clinical trial phases
 

Location

GEOGRAPHY

PBI Location Map

Key Features of the Reports

  • The report provides granular level information about the market size, regional market share, historic market (2018 to 2022) and forecast (2023 to 2029)
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments and startup’s details that are actively working in the market
  • The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario
  • The report analyses the impact of socio-political environment through PESTLE Analysis and competition through Porter’s Five Force Analysis in addition to recent technology advancements and innovations in the market

Frequently Asked Questions

2021 is the base year and 2028 is the forecast year.

The report covers the five regions and 15+ countries market data: North America (United States, Canada), Europe (Germany, France, Italy, Spain, and United Kingdom (UK), Asia Pacific (China, India, Japan, Australia & New Zealand), Latin America (Brazil, Mexico, Argentina) and Middle East and Africa (Saudi Arabia, United Arab Emirates, South Africa).

In our report, we provide 12-15 market players’ information into the report. However, based on the client’s request we will provide additional country and regional market players information as well.

[urltag url='request-table-of-content']

 

  • Pfizer
  • Bristol-Myers Squibb
  • Bayer
  • Janssen Research & Development, LLC
  • Daiichi Sankyo, Inc
  • BoehringerIngelheim
  • GlaxoSmithKline

Adjacent Markets